文献速递炎症性肠病

焦虑和抑郁导致炎症性肠病患者停用抗肿瘤坏死因子治疗

Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-07-12

在加拿大曼尼托巴省2001至2016年开始抗TNF治疗的1135例炎症性肠病患者中,15.7%在治疗前2年内符合焦虑和情绪障碍(AMD)的诊断标准。AMD显著增加停用抗TNF治疗的风险(调整HR 1.28;95%CI 1.03-1.59),AMD与后续IBD相关不良结局无关联。

要点

  • 开始抗TNF前2年内有AMD的IBD患者停用治疗风险增加(调整HR 1.28;95%CI 1.03-1.59)。
  • AMD与抗TNF启动后1年内停药风险增加相关(HR 1.50;95%CI 1.15-1.94)。
  • AMD与后续IBD相关不良结局(住院、手术、激素使用、换药或死亡)无关联。

核心结论

  • 开始抗TNF治疗前2年内有AMD的IBD患者,与无AMD的IBD患者相比,停用抗TNF治疗的风险增加。
  • 需要研究确定治疗AMD是否能提高治疗依从性。

研究设计与样本

  • 基于加拿大曼尼托巴省2001年至2016年开始抗TNF治疗的IBD患者的人群研究。
  • 共纳入1135例开始抗TNF治疗的IBD患者,其中178例(15.7%)在治疗前2年内符合AMD的行政诊断定义。
  • 采用生存分析评估活动性AMD与抗TNF停药及首次IBD相关不良结局的关联,并用Cox比例风险多变量回归模型校正人口学和临床因素。

主要发现

  • AMD显著增加停用抗TNF治疗的风险(调整HR 1.28;95%CI 1.03-1.59)。
  • AMD与抗TNF启动后1年内停药风险增加相关(HR 1.50;95%CI 1.15-1.94)。
  • AMD与后续IBD相关不良事件风险无关联。

关键数值与推荐

  • IBD相关不良结局定义为IBD相关住院或手术、新发或复发使用皮质类固醇、换用另一种抗TNF或死亡。
  • AMD诊断基于经过验证的行政定义,评估窗口为开始抗TNF治疗前2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要研究确定治疗AMD是否能提高治疗依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Anxiety and mood disorders (AMDs) are common among persons with inflammatory bowel diseases (IBD) and are associated with increased health care use and lower quality of life. We assessed the effects of AMDs on persistence on anti-tumor necrosis factor (anti-TNF) therapy in patients with IBD, and risk of IBD-related adverse outcomes after therapy initiation. METHODS: We identified all persons with IBD in Manitoba, Canada who were dispensed an anti-TNF agent from 2001 through 2016 and then identified those with a validated administrative definition of AMD in the 2 years before initiation of therapy. Survival analysis was used to assess the association between active AMDs and anti-TNF discontinuation and the first occurrence of an IBD-related adverse outcome (defined as IBD-related hospitalization or surgery, new or recurrent corticosteroid use, switching to an alternative anti-TNF, or death). We used Cox proportional hazards multivariable regression models to adjust for demographic and clinical factors associated with outcomes. RESULTS: We identified 1135 persons with IBD who began anti-TNF therapy; 178 of these patients (15.7%) met the diagnostic criteria for an AMD. AMDs significantly increased risk of discontinuation of anti-TNF therapy (adjusted hazard ratio, 1.28; 95% CI, 1.03-1.59) and discontinuation in the 1 year following anti-TNF initiation (hazard ratio, 1.50; 95% CI, 1.15-1.94). There was no association between AMDs and subsequent risk of IBD-related adverse events. CONCLUSIONS: Patients with IBD and an AMD within 2 years before starting anti-TNF therapy are at increased risk of discontinuing therapy, compared to patients with IBD without AMD. Studies are needed to determine if treatment of AMDs increases compliance with treatment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dolovich C, Bernstein CN, Singh H, et al. Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32668341. doi:10.1016/j.cgh.2020.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。